Navigation Links
Laureate Pharma Reports Record Growth for 2007
Date:4/1/2008

Continued Momentum Results in 131.4% Increase in Revenue and Positive

EBITDA for Three Consecutive Quarters

PRINCETON, N.J., April 1 /PRNewswire/ -- Laureate Pharma, Inc., a full- service biopharmaceutical development and protein production company, today announced record growth in revenues for 2007. The company posted a 131.4% increase over the same period last year and generated positive EBITDA for the third consecutive quarter. Laureate achieved other milestones in 2007, including a commissioned new Pilot Plant, an expanded facility that includes a new warehouse, a 30% increase in the company's workforce, a new strategic alliance, and the election of a new non-executive Chairman. In addition, the company signed major biopharmaceutical development and manufacturing agreements and several fill/finish agreements. Collectively, these factors position the company for continued growth and momentum for 2008 and beyond.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080131/NETH020LOGO )

"We continue to see strong growth in our client base and increasing demand for contract manufacturing services," said Robert Broeze, President and Chief Executive Officer at Laureate Pharma. "Laureate Pharma has superior bioprocessing capabilities specifically focused on monoclonal antibodies and recombinant proteins expressed in mammalian cells. We help our clients get the most out of their biopharmaceutical development programs by enabling them to capitalize on our expertise and experience in the areas of biopharmaceutical development and production. This inevitably helps them to get their new products into the clinic faster. We are excited about our continued business momentum and are extremely pleased with Laureate's overall performance in 2007. We are on track for another record year in 2008."

"Laureate Pharma grew their revenue 131.4% year-over-year and reported three consecutive quarters of EBITDA positive results," said James A. Datin, Executive Vice President and Managing Director of the Life Sciences Group at Safeguard Scientifics. "This represents a solid performance from a solid company. We are delighted with Laureate's milestones and achievements and look forward to seeing their continued growth." Safeguard Scientifics acquired Laureate in December 2004, providing the company with growth capital, operational and management support to achieve its strategic plan.

About Laureate Pharma

Laureate Pharma is a full-service biopharmaceutical development and protein production company located in Princeton, New Jersey. Laureate Pharma offers superior bioprocessing services that accelerate new products from development through production. Laureate provides a wide range of specialized services from process design and development to full-scale cGMP production, purification, aseptic filling, testing, validation, analytical services, and regulatory support. Laureate is focused on two active segments of the biopharmaceutical industry: monoclonal antibodies and recombinant protein products. Laureate Pharma, Inc. is a wholly owned subsidiary of Safeguard Scientifics, Inc. For more information, contact Michael Cavanaugh, Vice President Sales, Marketing, and Business Development at (609) 919-3400, or info@laureatepharma.com or visit http://www.laureatepharma.com.

About Safeguard Scientifics

Founded in 1953 and based in Wayne, PA, Safeguard Scientifics, Inc. (NYSE: SFE) provides growth capital for entrepreneurial and innovative technology and life sciences companies. Safeguard targets technology companies in Software as a Service (SaaS), Technology-Enabled Services and Internet- based Businesses, and life sciences companies in Molecular and Point-of-Care Diagnostics, Medical Devices and Specialty Pharmaceuticals with capital requirements between $5 and $50 million. Safeguard participates in expansion financings, corporate spin-outs, management buyouts, recapitalizations, industry consolidations and early-stage financings. http://www.safeguard.com


'/>"/>
SOURCE Laureate Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Thomson Scientific Salutes Nobel Laureate Prize Winners, Many of Whom Were Selected as Thomson Scientific Laureates in 2006
2. American Scientists Named as Laureates of the 2008 (24th) Japan Prize
3. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
4. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
5. Laureate Pharma Appoints Gary Swan as Vice President of Operations
6. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
7. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
8. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
9. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
10. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
11. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... PARK, Calif. and GREENWICH, ... Capital, a private investment firm focused on venture ... announced the promotion of Josh Richardson , ... focuses on investments in biotechnology companies.  He is ... has played important roles in Longitude,s investments in ...
(Date:2/16/2017)... CALABASAS, Calif. , Feb. 16, 2017 /PRNewswire/ ... on developing groundbreaking therapies to treat severe neurological ... in children treated with AGT-181, the company,s investigational ... syndrome (also known as mucopolysaccharidosis type I, or ... Phase 2 proof-of-concept (POC) study, presented today at ...
(Date:2/16/2017)... LOS ANGELES , Feb. 16, 2017 /PRNewswire/ ... CAPR ), a clinical-stage biotechnology company developing first-in-class ... today announced that it has elected to terminate ... to natriuretic peptide receptor agonists, including Cenderitide. ... a strategic move as we prioritize our efforts ...
(Date:2/16/2017)... February 16, 2017 Patient ... of innovative telemedicine application, new and leading edge ... experiencing a boom worldwide. The healthcare sector as ... technologies, services and new therapies for companies such ... RHT), Cellectar Biosciences, Inc. (NASDAQ: CLRB ...
Breaking Biology Technology:
(Date:1/25/2017)... , Jan. 25, 2017 The Elements ... Management (IAM) lifecycle is comprised of a comprehensive ... the purpose of maintaining digital identities and providing ... and applications. There are significant number of programs ... time to time by optimizing processes and changing ...
(Date:1/23/2017)...  The latest mobile market research from Acuity Market ... The quarterly average price of a biometric smartphone decreased ... 2016.  There are now 120 sub-$150 models on the ... just 28 a year ago at an average price ... Most , Acuity Market Intelligence Principal, "Biometric Smartphones are ...
(Date:1/19/2017)... , Jan. 19, 2017 ... user experience and security for consumer electronics, and ... payment processing systems and cybersecurity solutions, today announced ... enterprises and financial institutions worldwide to bolster security ... the end-to-end secure user authentication platforms they offer, ...
Breaking Biology News(10 mins):